ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
15.37
+0.74 (5.06%)
At close: Nov 5, 2025, 4:00 PM EST
15.20
-0.17 (-1.11%)
Pre-market: Nov 6, 2025, 8:42 AM EST
ADMA Biologics Revenue
ADMA Biologics had revenue of $134.22M in the quarter ending September 30, 2025, with 12.00% growth. This brings the company's revenue in the last twelve months to $488.56M, up 27.62% year-over-year. In the year 2024, ADMA Biologics had annual revenue of $426.45M with 65.15% growth.
Revenue (ttm)
$488.56M
Revenue Growth
+27.62%
P/S Ratio
7.48
Revenue / Employee
$713,225
Employees
685
Market Cap
3.67B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 426.45M | 168.24M | 65.15% |
| Dec 31, 2023 | 258.22M | 104.13M | 67.59% |
| Dec 31, 2022 | 154.08M | 73.14M | 90.36% |
| Dec 31, 2021 | 80.94M | 38.72M | 91.72% |
| Dec 31, 2020 | 42.22M | 12.87M | 43.85% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ADMA News
- 5 hours ago - ADMA Biologics, Inc. (ADMA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 16 hours ago - ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 8 days ago - ADMA Biologics to Report Third Quarter 2025 Financial Results on November 5, 2025 - GlobeNewsWire
- 21 days ago - 3 Biotech Stocks I Am Accumulating - Seeking Alpha
- 2 months ago - ADMA Biologics: Strong Product Mix, Growing Margins And Compelling Upside - Seeking Alpha
- 3 months ago - ADMA Biologics: Optionality With SG-001 And A Vertically Integrated IG Platform - Seeking Alpha
- 3 months ago - ADMA Biologics: A Better Quarter Than Headline Numbers - Seeking Alpha
- 3 months ago - ADMA Biologics, Inc. (ADMA) Q2 2025 Earnings Call Transcript - Seeking Alpha